Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.

ABSTRACT:

Background

In parallel to the increasing prevalence of metabolic syndrome, the prevalence of hepatic steatosis has also increased dramatically worldwide. Hepatic steatosis is a major risk factor of hepatic cirrhosis, cardiovascular disease and type 2 diabetes. Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) have been positively associated with the metabolic syndrome. However, the association between PCSK9 and the liver function is still controversial.

Objective

The objective of this study is to investigate the association between circulating PCSK9 levels and the presence of hepatic steatosis, as well as with liver biomarkers in a cohort of healthy individuals.

Methods

Total PCSK9 levels were measured by an in-house ELISA using a polyclonal

SUBMITTER: Paquette M 

PROVIDER: S-EPMC7614815 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature